This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Spherix Incorporated engages in the biotechnology research and development business. It is involved in developing SPX106T for treating high triglycerides and other dyslipidemias with a combination of D-tagatose and SPX106 drug compounds.View SPEX key stats
Spherix Inc - SPEX - EQUITY
Reviewed By: TheStreet Ratings on .
Report Summary: TheStreet Ratings team rates Spherix Inc as a
Sell with a ratings score of E+.
Report Snippet: We rate SPHERIX INC (SPEX) a SELL. This is based on the dominance of unfavorable investment measures, which should drive this stock to significantly underperform the majority of stocks that we rate. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow, generally disappointing historical performance in the stock itself and poor profit margins.